Antiangiogenic therapy with bevacizumab—a monoclonal antibody targeting circulating vascular endothelial growth factor A (VEGF-A) and inhibiting its interaction with VEGF receptors (VEGFR)—is reserved for recurrent GBM cases [15]. Here, VEGFA is linked to glioblastoma.